“Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice.” Brigitte Benard, Valérie Bastien, Benjamin Vinet, Roger Yang, Maja Krajinovic and Francine M. Ducharme. Eur Respir J 2017; 50: 1700148.

This article from the August 2017 issue of the European Respiratory Journal was published with an error in the abstract stating that the United States Food and Drug Administration (FDA) had issued a black box warning for montelukast. The warning issued by the FDA was not a black box warning. The corrected sentence reads as follows:“Although montelukast is generally well tolerated, postmarketing studies have reported serious neuropsychiatric adverse drug reactions (ADRs) leading to a United States Food and Drug Administration warning.”The article has been corrected and republished online.